Precision medicine and personalized health care call for reproducible and standardized predictive and prognostic biomarkers that can influence the clinical management of patients with cancer. In colorectal cancer, tumour budding — a histological manifestation of tumour cell invasion that is likened to epithelial–mesenchymal transition — is now emerging as one such factor.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lugli, A. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 30, 1299–1311 (2017).
Rogers, A. C. et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br. J. Cancer 115, 831–840 (2016).
Grigore, A. D., Jolly, M. K., Jia, D., Farach-Carson, M. C. & Levine, H. Tumor budding: the name is EMT. Partial EMT. J. Clin. Med. https://doi.org/10.3390/jcm5050051 (2016).
De Smedt, L. et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br. J. Cancer 116, 58–65 (2017).
Knudsen, K. N., Lindebjerg, J., Nielsen, B. S., Hansen, T. F. & Sorensen, F. B. MicroRNA-200b is downregulated in colon cancer budding cells. PLOS One 12, e0178564 (2017).
Galvan, J. A. et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 6, 874–885 (2015).
Bronsert, P. et al. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J. Pathol. 234, 410–422 (2014).
Centeno, I. et al. DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive. Virchows Arch. 470, 341–346 (2017).
Lugli, A. et al. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br. J. Cancer 101, 1382–1392 (2009).
Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. & Kirchner, T. Opinion: migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744–749 (2005).
The authors would like to acknowledge J. R. Jass, our friend and mentor who inspired much of the original works on tumour budding in CRC, as well as our colleagues from the International Tumour Budding Consensus Conference.
The authors declare no competing financial interests.
About this article
Cite this article
Zlobec, I., Lugli, A. Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nat Rev Cancer 18, 203–204 (2018). https://doi.org/10.1038/nrc.2018.1
Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods
Scientific Reports (2021)
Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model
Laboratory Investigation (2021)
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)
British Journal of Cancer (2021)
Nature Reviews Clinical Oncology (2021)
Validation of the International Tumor Budding Consensus Conference (ITBCC) 2016 recommendation in squamous cell carcinoma of the lung—a single-center analysis of 354 cases
Modern Pathology (2020)